Ben Woolven

Ben is the Business Strategy and Operations Partner of Syncona Investment Management Ltd.

Ben joined Syncona from GlaxoSmithKline where he has over a decade of strategy development, business operations and project management experience. Latterly Ben worked with GlaxoSmithKline’s Chief Medical Officer, where he led reconfiguration of global and regional medical functions in anticipation of their evolving pharma portfolio. Prior to this, Ben held various strategy and operations roles building scientific teams, developing justifications for new scientific investments, leading project management offices and providing R&D consultancy support, including a secondment to L.E.K Consulting. Prior to joining GlaxoSmithKline Ben played a key role in the success of Domantis, an antibody fragment start-up, sold to GlaxoSmithKline for £230 million. Ben holds a PhD in Immunology.